• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

CRISPR – genecards.org, UCSC, NM/OK, Caribou BioSciences

UNDATED on 3/8/2016

 

Jennifer Doudna Has Won A CRISPR Gene-Editing Patent

Now, the field is trying to figure out what Caribou Biosciences’ latest patent means.

Originally posted on Feb. 16, 2016, at 6:51 p.m.Updated on Feb. 17, 2016, at 7:52 p.m.

http://www.buzzfeed.com/stephaniemlee/new-crispr-patent#.hkyEyBo2W1

 

CRISPR – genecards.org, UCSC, NM/OK, Caribou BioSciences

Is it possible to go to the dashboard, all posts and click on your Name, you will get the Universe of ~200 articles that you published.

HOW one could search or one needs to visually glance at the title of each — so as to pull a subset of posts that are dedicated to a GENE.

Create an Excel File, place each gene inside and go to Weizmann Institute’s genecards.org and pullout from them respective data on that gene

By so doing we will have LPBI’s Gene Inventory which we could reference in the Drug Discovery process, we do more and more, as we are aggregating all Biologics under the Joint Venture with SBH Sciences, Inc.

In light of :

Leadership in Genomics: VarElect – Variants in Disease and UCSC Genome Technology Center

http://pharmaceuticalintelligence.com/2016/02/17/leadership-in-genomics-varelect-variants-in-disease-and-ucsc-genome-technology-center/

My Questions are:

1. HOW could we take this “to be create Excel File” to be published a PAGE, Password Protected as your Curation, it needs to have a Parent or a Hierarchy of Nesting in the Website architecture

And subject that to your our search into New Medicine, Inc. NM/OK DB for data complementarity compilation?

2. What Foundation Medicine, Now Roche, does have vs. Weizmann Institute’s genecards.org

 http://www.genecards.org/

I read and I visited genecards.org

Most interesting is

http://www.genecards.org/cgi-bin/carddisp.pl?gene=ALB#drugs_compounds

3. Will Weizmann Institute’s genecards.org be interested in New Medicine, Inc., NM/OK DB?

4. I have explored with Foundation Medicine, Now, Roche regarding New Medicine, Inc., NM/OK DB and their reply was that they focus ONLY on Genomics data in Cancer, thus,, no interest in New Medicine, Inc. NM/OK DB, there

5. What is in Weizmann Institute’s genecards.org that is NOT in UC Santa Cruz DBs ?

http://pharmaceuticalintelligence.com/2016/02/17/leadership-in-genomics-varelect-variants-in-disease-and-ucsc-genome-technology-center/

6. If you would take EACH ENTRY in this “to be create Excel File” and supplement it with

6.1 Weizmann Institute’s genecards.org

6.2 UC Santa Cruz DBs

6.3 New Medicine, Inc., NM/OK DB – given this is a GENE in the cancer implication

6.4 A RECORD of the outputs from 6.1, 6.2, 6.3 being created 

7. THEN we could target 6.4 for CRISPR and go to 

http://rna.berkeley.edu/crispr.html

http://rna.berkeley.edu/contact.html

DNA interrogation by the CRISPR RNA-guided endonuclease Cas9

Samuel H. Sternberg, Sy Redding, Martin Jinek, Eric C. Greene & Jennifer A. Doudna Nature 507, 62–67 (06 March 2014) doi:10.1038/nature13011

http://www.nature.com/nature/journal/v507/n7490/full/nature13011.html

and

http://rna.berkeley.edu/translation.html

http://alumni.berkeley.edu/california-magazine/winter-2014-gender-assumptions/cracking-code-jennifer-doudna-and-her-amazing

8. Doudna started her professorship at Yale University in 1994. While the group was able to grow high-quality crystals, they struggled with the phase problem due to unspecific binding of the metal ions. One of her early graduate students and later her husband, Jamie Cate decided to soak the crystals in osmium hexamine to imitate magnesium. Using this strategy, they were able to solve the structure, the second solved folded RNA structure since tRNA.[9][10] The magnesium ions would cluster at the center of the ribozyme and would serve as a core for RNA folding similar to that of a hydrophobic core of a protein.[5]

9. In 2015, Doudna gave a TED Talk about the bioethics of using CRISPR. [13]

“Jennifer Doudna TED Talk”.

Lastly,

10. Caribou BioSciences

http://cariboubio.com/application-areas/therapeutics

Precision medicines have the ability to transform healthcare and treat a myriad of unmet medical needs. The Caribou technology platform has the ability to generate transformative medicines in multiple different market segments.

Our current therapeutic areas of exploration include anti-microbials, animal health, and therapeutic bioproduction.

Human therapeutics

In 2014, Caribou co-founded Intellia Therapeutics to develop curative medicines utilizing the Caribou CRISPR-Cas9 platform. Rachel Haurwitz, President and Chief Executive Officer of Caribou, is a member of Intellia’s Board of Directors.

Intellia is developing human gene and cell therapies for both ex vivo and in vivo applications using CRISPR-Cas9 gene editing technology. Near-term ex vivo applications include the treatment of blood disorders and cancer. In January 2015, Intellia announced a five-year research and development collaboration with Novartis to accelerate the ex vivo development of new CRISPR-Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs).

Caribou Bio Grants IDT Non-Exclusive Rights to Commercialize RUO CRISPR/Cas9 Reagents

Feb 23, 2016
a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – Caribou Biosciences today announced it has granted Integrated DNA Technologies the rights to commercialize CRISPR/Cas9 reagents.

Under the terms of the non-exclusive license agreement, IDT has worldwide rights to sell CRISPR/Cas9 reagents for research use only.

Financial and other details were not disclosed

“IDT is excited to be the first genomics company to have reached this agreement with Caribou,” IDT President and CEO Joseph Walder said in a statement. “This license allows us to deliver the entire spectrum of products for CRISPR/Cas9 genome editing, solidifying our position at the forefront of this groundbreaking technology.” IDT currently offers the Alt-R CRISPR/Cas9 System for genome editing, which provides RNA reagents featuring shortened, synthetic RNA oligonucleotides that don’t activate innate cellular immune responses.

Caribou’s CRISPR-related intellectual property comes from several sources. The University of California has exclusively licensed to the firm patent rights associated with UC-Berkeley Professor and Caribou Co-founder Jennifer Doudna. Caribou has also cross-licensed CRISPR IP with DuPont Pioneer.

The University of California is the senior party in an upcoming interference proceeding to settle certain claims in battle over a foundational CRISPR/Cas9 patent; the Broad Institute is the junior party.

Caribou has licensed CRISPR IP to several companies including Sage Labs, acquired in 2014 by Horizon Discovery, to create genetically engineered research animals, and to pharmaceutical giant Novartis, which has an option to non-exclusively license the CRISPR/Cas9 platform for research applications.

https://www.genomeweb.com/gene-silencinggene-editing/caribou-bio-grants-idt-non-exclusive-rights-commercialize-ruo-crisprcas9?utm_source=SilverpopMailing&utm_medium=email&utm_campaign=Daily%20News:%20Caribou%20Bio%20Grants%20IDT%20Non-Exclusive%20Rights%20to%20Commercialize%20RUO%20CRISPR/Cas9%20Reagents%20-%2002/23/2016%2011:15:00%20AM

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,978 other subscribers

  • Recent Posts

    • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
    • Sperm epigenetic clock and pregnancy outcomes May 14, 2022
    • Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
    • Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
    • Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
    • Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
    • 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
    • We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
    • The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines   April 22, 2022
    • The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 Rosalind Codrington, PhD
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: